Associated Papers
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
41179686 (PubMed )
Supplement: Table3.xls › Mutations_in_after_120d_TISF
Molecular genetic analysis of colorectal carcinoma with an aggressive extraintestinal immunohistochemical phenotype.
Hrudka J et al.
Scientific Reports, 2024
39333321 (PubMed )
Supplement: 41598_2024_72687_MOESM2_ESM.xlsx › 24
Arginines of the CGN codon family are Achilles' heels of cancer genes.
Trexler M et al.
Scientific Reports, 2024
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.
Zivanovic A et al.
Nar Cancer, 2023
37636316 (PubMed )
Supplement: zcad045_supplemental_files.zip › SupplementaryDataS12.xlsx › Sheet_1
Landscape of Genomic Alterations in IDH Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor.
Yan Y et al.
Jco Precision Oncology, 2020
Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
He CY et al.
Clinical and Translational Medicine, 2020
32508039 (PubMed )
Supplement: CTM2-10-353-s003.xlsx › Table_S3
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_9_Accuracy_Short_Variant_Line_Data.xlsx › sheet_1
Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
Saadeh FS et al.
Plos One, 2020
33237934 (PubMed )
Supplement: pone.0242793.s003.xlsx › Sheet1
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL et al.
European Journal of Cancer (oxford, England : 1990), 2019
31543384 (PubMed )
Supplement: mmc2.xlsx › FFPE_variants-V1_vs_V2
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K et al.
Cancer Science, 2019
30742731 (PubMed )
Supplement: CAS-110-1480-s003.xlsx › Table_S3
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA et al.
Acta Neuropathologica Communications, 2018
30333046 (PubMed )
Supplement: 40478_2018_613_MOESM3_ESM.xlsx › Sheet1
Next-generation sequencing in patients with advanced cancer: are we ready for widespread clinical use? A single institute's experience.
Grenader T et al.
Anti-cancer Drugs, 2016
Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.
Nasrallah MP et al.
Academic Pathology, 0
31206012 (PubMed )
Supplement: Supplementary_Table_2__1_.xlsx › table_egfrviii_and_solid_panel_
Select a paper to view details